263 related articles for article (PubMed ID: 23843898)
1. Urokinase plasminogen activator receptor (uPAR) targeted nuclear imaging and radionuclide therapy.
Li D; Liu S; Shan H; Conti P; Li Z
Theranostics; 2013; 3(7):507-15. PubMed ID: 23843898
[TBL] [Abstract][Full Text] [Related]
2. Structure-driven design of radionuclide tracers for non-invasive imaging of uPAR and targeted radiotherapy. The tale of a synthetic peptide antagonist.
Ploug M
Theranostics; 2013; 3(7):467-76. PubMed ID: 23843894
[TBL] [Abstract][Full Text] [Related]
3. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
[TBL] [Abstract][Full Text] [Related]
4. Rational targeting of the urokinase receptor (uPAR): development of antagonists and non-invasive imaging probes.
Kriegbaum MC; Persson M; Haldager L; Alpízar-Alpízar W; Jacobsen B; Gårdsvoll H; Kjær A; Ploug M
Curr Drug Targets; 2011 Nov; 12(12):1711-28. PubMed ID: 21707479
[TBL] [Abstract][Full Text] [Related]
5. Antibody-based PET of uPA/uPAR signaling with broad applicability for cancer imaging.
Yang D; Severin GW; Dougherty CA; Lombardi R; Chen D; Van Dort ME; Barnhart TE; Ross BD; Mazar AP; Hong H
Oncotarget; 2016 Nov; 7(45):73912-73924. PubMed ID: 27729618
[TBL] [Abstract][Full Text] [Related]
6. The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single target.
O'Halloran TV; Ahn R; Hankins P; Swindell E; Mazar AP
Theranostics; 2013; 3(7):496-506. PubMed ID: 23843897
[TBL] [Abstract][Full Text] [Related]
7. Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications.
Persson M; Kjaer A
Clin Physiol Funct Imaging; 2013 Sep; 33(5):329-37. PubMed ID: 23701192
[TBL] [Abstract][Full Text] [Related]
8. Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation.
Cunningham O; Campion S; Perry VH; Murray C; Sidenius N; Docagne F; Cunningham C
Glia; 2009 Dec; 57(16):1802-14. PubMed ID: 19459212
[TBL] [Abstract][Full Text] [Related]
9. Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors.
Mauro CD; Pesapane A; Formisano L; Rosa R; D'Amato V; Ciciola P; Servetto A; Marciano R; Orsini RC; Monteleone F; Zambrano N; Fontanini G; Servadio A; Pignataro G; Grumetto L; Lavecchia A; Bruzzese D; Iaccarino A; Troncone G; Veneziani BM; Montuori N; Placido S; Bianco R
Sci Rep; 2017 Aug; 7(1):9388. PubMed ID: 28839232
[TBL] [Abstract][Full Text] [Related]
10. Expression and localization of urokinase-type plasminogen activator receptor in bovine cumulus-oocyte complexes.
García DC; Miceli DC; Rizo G; García EV; Valdecantos PA; Roldán-Olarte M
Zygote; 2016 Apr; 24(2):230-5. PubMed ID: 25939353
[TBL] [Abstract][Full Text] [Related]
11. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
12. uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy.
Lund IK; Illemann M; Thurison T; Christensen IJ; Høyer-Hansen G
Curr Drug Targets; 2011 Nov; 12(12):1744-60. PubMed ID: 21707477
[TBL] [Abstract][Full Text] [Related]
13. Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration.
Duriseti S; Goetz DH; Hostetter DR; LeBeau AM; Wei Y; Craik CS
J Biol Chem; 2010 Aug; 285(35):26878-26888. PubMed ID: 20501655
[TBL] [Abstract][Full Text] [Related]
14. Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model.
Zhang J; Sud S; Mizutani K; Gyetko MR; Pienta KJ
Neoplasia; 2011 Jan; 13(1):23-30. PubMed ID: 21245937
[TBL] [Abstract][Full Text] [Related]
15. The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling.
Carriero MV; Stoppelli MP
Curr Pharm Des; 2011; 17(19):1944-61. PubMed ID: 21711235
[TBL] [Abstract][Full Text] [Related]
16. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
[TBL] [Abstract][Full Text] [Related]
17. Urokinase plasminogen activator system as a potential target for cancer therapy.
Mekkawy AH; Morris DL; Pourgholami MH
Future Oncol; 2009 Nov; 5(9):1487-99. PubMed ID: 19903074
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of uPA/uPAR inhibits intermittent hypoxia-induced epithelial-mesenchymal transition (EMT) in DAOY and D283 medulloblastoma cells.
Gupta R; Chetty C; Bhoopathi P; Lakka S; Mohanam S; Rao JS; Dinh DE
Int J Oncol; 2011 Mar; 38(3):733-44. PubMed ID: 21181094
[TBL] [Abstract][Full Text] [Related]
19. Role of urokinase receptor in tumor progression and development.
Noh H; Hong S; Huang S
Theranostics; 2013; 3(7):487-95. PubMed ID: 23843896
[TBL] [Abstract][Full Text] [Related]
20. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]